Stephen Opat

Jul 31, 2024 | onclive.com | Stephen Opat

Stephen Opat, MBBS, director, Clinical Hematology, head, Department of Hematology, School of Clinical Sciences, Monash Health, Monash University; founder, chair, the Australasian Lymphoma and Related Diseases Registry, lead investigator, the Melbourne Genomics Health Alliance Lymphoma Flagship, discusses the accessibility and clinical implications of the combination of sonrotoclax (BGB-11417) and zanubrutinib (Brukinsa) in the treatment of patients with relapsed/refractory chronic lymphocytic...

Jul 29, 2024 | onclive.com | Stephen Opat

Stephen Opat, MBBS, director, Clinical Hematology, head, Department of Hematology, School of Clinical Sciences, Monash Health, Monash University; founder, chair, the Australasian Lymphoma and Related Diseases Registry, lead investigator, the Melbourne Genomics Health Alliance Lymphoma Flagship, discusses the combination of sonrotoclax (BGB-11417) and zanubrutinib (Brukinsa) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

May 30, 2024 | onlinelibrary.wiley.com | Jake shortt |Stephen Opat

In their paper the authors report their experience applying the EuroClonality NGS DNA Capture (EuroClonality-NDC) assay to plasma from diffuse large B-cell lymphoma (DLBCL) patients receiving first-line chemoimmunotherapy.1 This study further adds to the evidence for the use of liquid biopsy in lymphoma management, as previously demonstrated with other NGS-based platforms.2-4 Of note, this is the first publication utilising cell-free tumour DNA (ctDNA) as input to the EuroClonality-NDC assay,...